Tirzepatide vs Semaglutide: Which One is Better for Weight Loss?

By WPG Research Team•Updated April 4, 2026

Disclosure: Some links on this site are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you. Thank you for supporting our site.·For informational purposes only—not medical advice.

The Short Answer

Tirzepatide produces more weight loss. In the first head-to-head clinical trial (published in the New England Journal of Medicine, May 2025), tirzepatide beat semaglutide on every measure:

	Tirzepatide (Zepbound)	Semaglutide (Wegovy)
Average weight loss	20.2% (~50 lbs)	13.7% (~34 lbs)
Lost 25%+ body weight	31.6%	16.1%
Waist reduction	7.2 inches	5.1 inches
Quit due to stomach issues	2.7%	5.6%

Source: SURMOUNT-5 trial, N Engl J Med 2025

But here is what actually matters: The best medication is the one you can get, afford, and stay on. Keep reading—we will help you figure out which one fits your situation.

Start Here: Which One Matches Your Situation?

Before comparing clinical data, let us match you to the right medication based on what is actually going on in your life.

You have obesity AND sleep apnea

Ask about Zepbound (tirzepatide)

Zepbound is FDA-approved specifically for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). This indication often helps with insurance approval.

You have obesity AND heart disease

Ask about Wegovy (semaglutide)

Wegovy is FDA-approved to reduce heart attack, stroke, and cardiovascular death in adults with obesity and established heart disease (March 2024). In the SELECT trial, it reduced major cardiovascular events by 20%. This is the strongest evidence either drug has for outcomes beyond weight loss.

You have obesity AND fatty liver disease (MASH)

Ask about Wegovy (semaglutide)

Wegovy received accelerated FDA approval for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver scarring in 2025.

You have type 2 diabetes

Both work, but tirzepatide has an edge

In the SURPASS-2 trial comparing them directly in people with diabetes, tirzepatide produced better A1C reduction (2.46% vs 1.86%) and more weight loss (12.4% vs 6.2%). However, if you have diabetes PLUS heart disease, semaglutide's cardiovascular outcomes data may tip the balance.

You want maximum weight loss

Tirzepatide has the edge

Head-to-head data shows tirzepatide produces about 47% more weight loss than semaglutide. For someone starting at 250 lbs, that is roughly 50 lbs lost vs. 34 lbs.

You really do not want to do injections

Semaglutide has a tablet option

Wegovy is now available as a daily 25mg tablet (FDA approved December 22, 2025). The oral version produced 16.6% weight loss in trials—less than injectable Wegovy but still substantial. There is no tirzepatide pill. For a complete breakdown of oral tirzepatide alternatives and options, check our comprehensive guide.

You are on birth control pills

Important consideration for tirzepatide

Tirzepatide can reduce how well oral contraceptives work. Eli Lilly recommends using backup contraception (condoms, etc.) for 4 weeks after starting and 4 weeks after each dose increase—or switching to an IUD or implant. This does not apply to semaglutide.

Your biggest concern is cost

Both now have similar cash-pay pricing

As of late 2025, both manufacturers offer self-pay programs around $349-499/month for people without insurance coverage. We cover this in detail below.

What These Medications Actually Are

Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones your body naturally produces after eating. They help you lose weight by:

Reducing hunger — You feel less urge to eat
Increasing fullness — You feel satisfied with smaller portions
Slowing digestion — Food stays in your stomach longer

The difference is in how they work:

	Semaglutide	Tirzepatide
Targets	1 hormone (GLP-1)	2 hormones (GLP-1 + GIP)
Brand for weight loss	Wegovy	Zepbound
Brand for diabetes	Ozempic	Mounjaro
Available forms	Weekly injection OR daily tablet	Weekly injection only
Manufacturer	Novo Nordisk	Eli Lilly
FDA approved (weight loss)	2021	2023

Why tirzepatide produces more weight loss: The dual-hormone approach (GIP + GLP-1) affects appetite and metabolism through two pathways instead of one. Think of it like having two keys instead of one.

The Head-to-Head Evidence (SURMOUNT-5)

Until late 2024, we only had indirect comparisons. Then the SURMOUNT-5 trial directly tested tirzepatide against semaglutide in 751 adults with obesity.

Trial details:

Duration: 72 weeks (about 1.5 years)
Participants: Adults with BMI 30+, or BMI 27+ with a weight-related condition
No type 2 diabetes
Doses: Maximum tolerated dose of each medication
Design: Open-label (patients knew which drug they were taking)
Published: New England Journal of Medicine, May 2025

Complete results:

What was measured	Tirzepatide	Semaglutide
Average weight loss (%)	20.2%	13.7%
Average weight loss (lbs)	50.3 lbs	33.1 lbs
Lost at least 10%	85.8%	70.9%
Lost at least 15%	71.5%	52.4%
Lost at least 20%	54.3%	30.4%
Lost at least 25%	31.6%	16.1%
Waist circumference lost	7.2 inches	5.1 inches

What this means in real pounds:

Starting weight	Tirzepatide avg loss	Semaglutide avg loss	Difference
200 lbs	40 lbs	27 lbs	13 lbs
250 lbs	50 lbs	34 lbs	16 lbs
300 lbs	61 lbs	41 lbs	20 lbs

The surprise finding on tolerability:

Fewer people quit tirzepatide due to side effects than quit semaglutide.

Stopped tirzepatide due to GI side effects: 2.7%
Stopped semaglutide due to GI side effects: 5.6%

This contradicts the common belief that tirzepatide has worse side effects. In the direct comparison, it was actually better tolerated.

One caveat: SURMOUNT-5 was open-label, meaning patients knew which drug they were getting. This does not invalidate the results, but expectation can influence outcomes in weight loss studies. Also, men lost about 6% less weight than women in both groups—something to discuss with your doctor if you are male.

Side Effects: What to Really Expect

Both medications cause similar side effects, mostly during the first few months while your dose is being increased.

What most people experience:

Side Effect	How Common	What It Feels Like
Nausea	17-24%	Queasiness, especially after eating too much
Diarrhea	12-22%	Loose stools, urgency
Vomiting	6-13%	Usually improves after first few weeks
Constipation	3-5%	Opposite problem for some
Stomach discomfort	5-7%	Cramping or bloating

The good news: Most side effects are mild to moderate, happen during dose increases, and get better as your body adjusts.

How to manage side effects:

Eat smaller meals
Avoid fatty or greasy foods
Stay well hydrated
Eat slowly
Do not lie down right after eating
Ask your doctor about anti-nausea medication during dose escalation

Serious risks (both medications)

Both medications carry a boxed warning about thyroid tumors (based on animal studies) and should NOT be used if you have:

Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Other concerns to discuss with your doctor:

Pancreatitis: Stop immediately if you have severe abdominal pain that will not go away
Gallbladder problems: Rapid weight loss increases gallstone risk
Kidney issues: Dehydration from vomiting/diarrhea can affect kidney function

Tirzepatide-specific warning (birth control):

Tirzepatide slows stomach emptying, which can affect how oral contraceptives absorb. If you are on the pill, use backup contraception for 4 weeks after starting and after each dose increase—or switch to an IUD or implant. This is in the prescribing information but many providers do not mention it.

What if you cannot tolerate one? If you have had trouble with semaglutide, tirzepatide might work better for you—or vice versa. The mechanisms overlap but are not identical. But never combine them. Both FDA labels explicitly warn against using with other GLP-1 medications.

What Nobody Tells You: Weight Comes Back When You Stop

This is the part most websites skip. We are including it because you deserve to know before you start.

The clinical evidence is clear:

Semaglutide: In a follow-up to the STEP 1 trial, participants who stopped semaglutide regained about two-thirds of their lost weight within one year.
Tirzepatide: In the SURMOUNT-4 trial, participants who stopped tirzepatide after initial weight loss regained substantial weight, while those who continued maintained their results.

What this means for you:

For many people, obesity is a chronic condition—like high blood pressure or diabetes. These medications work, but they work while you are taking them. When you stop, the biological drive to regain weight returns.

This is not a failure of willpower. It is physiology.

Before you start, think about:

Can I afford this long-term?
Is there a path to insurance coverage?
What is my plan if I lose access?

This is not meant to discourage you. It is meant to help you plan so you are not caught off guard later.

What These Medications Actually Cost

Cost is often the deciding factor. Here is the current reality.

List prices vs. what you will actually pay:

Medication	List Price	Self-Pay Programs	With Insurance + Savings Card
Zepbound	~$1,086/month	$299-$449/month	As low as $25/month
Wegovy	~$1,349/month	$349-$499/month	As low as $0/month

Zepbound (tirzepatide) cash-pay through LillyDirect:

2.5mg vials: $299/month
5mg vials: $399/month
7.5mg-15mg vials: $449/month

Note: These are single-dose vials requiring a syringe, not auto-injector pens. You must refill within 35 days to keep this pricing.

Wegovy (semaglutide) cash-pay through NovoCare:

First 2 months (0.25mg, 0.5mg): $199/month
After intro period (all doses): $349/month

72-Week Cost Comparison

Using SURMOUNT-5's trial length and typical titration:

Zepbound vials (LillyDirect pricing):

Month 1 (2.5mg): $299
Month 2 (5mg): $399
Months 3-18 (maintenance): $449 x 16 = $7,184

18-month total: $7,882

Wegovy (NovoCare pricing):

Months 1-2 (intro): $199 x 2 = $398
Months 3-18: $349 x 16 = $5,584

18-month total: $5,982

Cost per 1% body weight lost:

This is the metric no one else calculates:

Zepbound: $7,882 / 20.2% = $390 per 1% lost
Wegovy: $5,982 / 13.7% = $437 per 1% lost

Zepbound costs more upfront but delivers more weight loss per dollar. Wegovy costs less total but delivers less per dollar spent.

Insurance realities:

Insurance Type	What to Expect
Employer insurance	Coverage varies widely. Often requires prior authorization. Improving in 2025.
Medicare	Does NOT cover for weight loss alone. May cover for sleep apnea (Zepbound) or heart disease (Wegovy).
Medicaid	Limited. Varies significantly by state.

How to improve your chances of coverage:

Ask your doctor about applicable indications. If you have sleep apnea, Zepbound's OSA indication may help. If you have heart disease, Wegovy's CV indication may help.
Request a prior authorization rather than just filling a prescription. Your doctor's office can submit documentation.
Appeal if denied. First denials are common. Many get approved on appeal with additional documentation.
Use manufacturer savings cards. Even with insurance, these can reduce your copay to $25/month or less.

Switching Between Medications

Can you switch from Ozempic/Wegovy to Mounjaro/Zepbound?

Yes, with your doctor's guidance. Common reasons to switch:

Plateaued on semaglutide and want more weight loss
Side effects on one that might be better on the other
Insurance changed what they cover

How to switch: Most doctors restart tirzepatide at 2.5mg regardless of your previous semaglutide dose. You will go through the titration schedule again. The switch typically happens on your next scheduled injection day—just take the new medication instead of the old one.

Can you switch from tirzepatide to semaglutide?

Yes, though less common. Some people switch if they have cardiovascular concerns (semaglutide has SELECT trial data), want the oral option, or if their insurance situation changes.

Can you take both together?

No. Never. Both activate GLP-1 receptors. Taking both increases side effects without added benefit. Both FDA labels explicitly warn against this.

A Serious Warning About “Cheap” GLP-1 Medications

If you see tirzepatide or semaglutide offered at dramatically lower prices online, be extremely careful.

What the FDA has said:

Compounding pharmacies were temporarily allowed to make these medications during shortages. Those shortages are now resolved (semaglutide: February 2025, tirzepatide: October 2024). Compounded versions are no longer legally permitted in most cases.
Counterfeit Ozempic has been found in the U.S. supply chain. The FDA has issued warnings.
Adverse events have been reported with compounded GLP-1 products, including dosing errors that led to hospitalizations.

How to protect yourself:

Only get these medications from licensed, verified pharmacies
If the price seems too good to be true, it probably is
Brand-name medications come in sealed, manufacturer-labeled packaging
Verify any online pharmacy through your state board of pharmacy

How to Actually Get Started

Step 1: Check if you qualify

Both medications are FDA-approved for:

Adults with BMI 30+ (obesity), OR
Adults with BMI 27+ with at least one weight-related condition (high blood pressure, high cholesterol, sleep apnea, type 2 diabetes, heart disease, etc.)

Not sure of your BMI? A 5'4" woman qualifies at about 175 lbs (BMI 30) or 158 lbs with a related health condition (BMI 27).

Step 2: Prepare for your doctor visit

Bring:

Your current weight and height
List of any weight-related conditions you have
Your insurance card
Questions you want to ask

What to say: “I have been researching GLP-1 medications for weight loss. Based on my situation [mention any conditions like sleep apnea, heart issues, diabetes, etc.], I would like to discuss whether tirzepatide or semaglutide might be appropriate for me.”

Step 3: Check insurance BEFORE filling

Your doctor's office or pharmacy can verify coverage before you fill the prescription. Do not assume—check first.

Step 4: Apply for savings programs

Even with insurance, savings cards can significantly reduce your cost.

Zepbound: LillyDirect (pricinginfo.lilly.com/zepbound)
Wegovy: NovoCare (wegovy.com/coverage-and-savings)

Step 5: If your doctor will not prescribe

Some primary care doctors are not comfortable prescribing these medications. If that is your situation:

Ask for a referral to an obesity medicine specialist or endocrinologist
Consider telehealth providers that specialize in weight management

Dosing: What to Expect Week by Week

Both medications start low and gradually increase. This reduces side effects and helps your body adjust.

Semaglutide (Wegovy) schedule:

Weeks	Dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

Tirzepatide (Zepbound) schedule:

Weeks	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg
13-16	10 mg
17-20	12.5 mg
21+	15 mg (max)

Important: Not everyone needs the maximum dose. Your doctor may keep you at a lower dose if you are seeing good results with manageable side effects.

Questions to Ask Your Doctor

Based on my health history, which medication makes more sense for me?
What is a realistic weight loss goal and timeline for my situation?
How should I handle side effects in the first few weeks?
What happens if I plateau—do we increase the dose or try something else?
What is our plan if I need to stop for any reason?
(If applicable) Do I need to change my birth control method?

The Bottom Line

If you want maximum weight loss: Tirzepatide (Zepbound) is clinically superior based on head-to-head trial data.

If you have specific health conditions:

Sleep apnea + obesity → Zepbound has an FDA indication
Heart disease + obesity → Wegovy has an FDA indication and outcomes data
Fatty liver disease (MASH) → Wegovy has an FDA indication
Type 2 diabetes → Both work; tirzepatide slightly stronger for A1C and weight

If you prefer tablets over injections: Wegovy offers a daily tablet option.

If cost is the deciding factor: Both are now $350-500/month through manufacturer programs. Wegovy costs less total; Zepbound delivers more weight loss per dollar.

The most important factor: The medication that works is the one you can access, afford, and stay on long-term. Plan for this before you start.

Looking further ahead, next-generation triple agonists like retatrutide are showing even greater weight loss in clinical trials by targeting GLP-1, GIP, and glucagon receptors simultaneously. The GLP-1 landscape is evolving fast.

Frequently Asked Questions

Tirzepatide. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide—47% more relative weight loss.

Yes, same medication (tirzepatide), same doses. Zepbound is branded for weight loss; Mounjaro is branded for type 2 diabetes.

Same active ingredient (semaglutide), but Wegovy goes up to 2.4mg for weight loss while Ozempic maxes at 2mg for diabetes.

No. Both work on GLP-1 receptors. Combining them increases side effects without added benefit. Never take both.

In the head-to-head trial, tirzepatide actually had fewer dropouts due to GI side effects (2.7% vs 5.6%). Both cause nausea, but it typically improves after the first few weeks.

Check if you qualify for patient assistance programs (income-based). Ask your doctor about the diabetes versions (Mounjaro, Ozempic) which sometimes have different coverage. Consider whether any FDA indications (sleep apnea, heart disease) apply to you for insurance purposes.

Most likely, yes. Studies show people regain about two-thirds of lost weight within a year of stopping. These medications manage obesity; they do not cure it.

Yes, under doctor supervision. If you plateau on semaglutide or have side effects, switching to tirzepatide (or vice versa) is common. You will restart at the lowest dose.

The FDA has issued warnings about compounded GLP-1 products, including dosing errors and counterfeits. The shortages that allowed compounding have been resolved. Stick to brand-name from licensed pharmacies.

For semaglutide, yes—oral Wegovy (25mg daily) was approved on December 22, 2025. There is no tirzepatide pill yet.

Sources

Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131
Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107519
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
Wilding JPH, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide (STEP 1 Extension). Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725
FDA. Zepbound Prescribing Information. uspl.lilly.com/zepbound/zepbound.html
FDA. Wegovy Prescribing Information. accessdata.fda.gov
FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
FDA. Counterfeit Ozempic Warning. fda.gov
FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. February 2025.
Eli Lilly. Zepbound Pricing Information. pricinginfo.lilly.com/zepbound
Novo Nordisk. Wegovy Savings. wegovy.com/coverage-and-savings

Update History

December 29, 2025: Updated with SURMOUNT-5 full publication data; refreshed manufacturer pricing; added oral Wegovy information; added birth control interaction warning
February 21, 2025: FDA declared semaglutide shortage resolved
December 2024: SURMOUNT-5 topline results announced; Zepbound approved for sleep apnea
December 22, 2025: Oral Wegovy (25mg daily tablet) FDA approved for weight loss

This content is for informational purposes only and does not constitute medical advice. Tirzepatide and semaglutide are prescription medications with serious risks including a boxed warning about thyroid tumors. Individual results vary. Please consult with a licensed healthcare provider about whether they are appropriate for you.

How we rank + verify